No Data
Xuantai Pharmaceutical (688247.SH): Carbonate Sevelamer Tablets and Maxitentan Tablets are expected to be selected for the national Pharmaceutical centralized procurement.
Xuantai Pharmaceutical (688247.SH) announced that recently, the company participated in the tenth batch of national organization Pharmaceutical centralized volume procurement...
Xuantai Pharmaceutical (688247.SH): The company's products are participating in the national organization for centralized volume-based procurement of Pharmaceuticals and are expected to be selected.
Gelonghui, on December 13, announced that Xuantai Pharmaceutical (688247.SH) participated in the bidding for the tenth batch of national organized pharmaceutical centralized procurement. According to the document "Announcement of Proposed Selected Results for National Pharmaceutical Centralized Procurement" released by the National Organized Pharmaceutical Joint Procurement Office on December 12, 2024, the company's products, carbonic acid seviram tablets and macitentan tablets (products developed in collaboration with Puji Biological Technology (Taizhou) Co., Ltd.), were selected for this centralized procurement, while posaconazole enteric-coated tablets and tofacitinib citric acid extended-release tablets were not selected for this centralized procurement. The proposed selection results for this centralized procurement are intended.
Express News | Sinotherapeutics Says Key Shareholder Plans to Unload up to 2.4264% Stake in Company Within Three Months
We Think That There Are Some Issues For Sinotherapeutics (SHSE:688247) Beyond Its Promising Earnings
Third Quarter Report 2024
Xuantai Medicine (688247.SH): The net income for the first three quarters was 92.573 million yuan, a year-on-year increase of 110.00%.
On October 29, Gelonghui reported on the third quarter of 2024 for Xuantai Medicine (688247.SH). The company's revenue for the first three quarters was 0.363 billion yuan, a year-on-year increase of 69.95%; net income attributable to shareholders of the listed company was 92.573 million yuan, a year-on-year increase of 110.00%; basic earnings per share were 0.21 yuan.
No Data
